Pharmafile Logo
Pharmafocus logo
Advanced Search

Astellas

Showing 15 posts of 103 posts found.

christy_nolandweb

Astellas appoints comms head from Baxter

September 18, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Burson-Marsteller, Edelman, baxter, christy noland, including GolinHarris

Astellas has hired Christy Noland to be its new director of business communications and advocacy for its urology unit in …

Appointment

FDA approves new indication for Xtandi

September 11, 2014
Sales and Marketing Astellas, FDA, Medivation, Xtandi, Zytiga, prostate

The FDA has approved Astellas Pharma and Medivation’s prostate cancer drug Xtandi (enzalutamide) for use in patients who have not …

News
Astellas logo

Cancer Research UK and Astellas announce partnership

August 8, 2014
Medical Communications, Research and Development, Sales and Marketing Astellas, CRUK, Canncer, Pancreatic cancer

Cancer Research UK and its commercial arm, Cancer Research Technology (CRT) have announced they are joining forces with Astellas in …

News
jun_kono_astellas

Astellas Pharma announces new senior hires

August 7, 2014
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas

Astellas Pharma EMEA, the European division of Astellas Pharma, has appointed Simon Dew to the position of chief strategy officer …

Appointment
Yervoy image

NICE ‘yes’ for cancer drugs

July 23, 2014
Sales and Marketing Astellas, BMS, Cancer, NICE, Xtandi, Yervoy

Two big-name oncology brands, Bristol-Myers Squibb’s Yervoy and Astellas Pharma’s Xtandi, have been given the nod by drug costs watchdog …

News
tatjana_dragovic_astellas

Astellas names Americas head

July 1, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Tatjana Dragovic, americas

Astellas has appointed Tatjana Dragovic as its VP and regional compliance officer for the firm’s Americas region. In this role …

Appointment

NICE recommends Xtandi

May 9, 2014
Sales and Marketing Astellas, NICE, Xtandi, abiraterone, prostate

NICE has reiterated that Astellas Pharma’s Xtandi should be used to treat NHS prostate cancer patients – but has removed …

News

Lundbeck teams up with Lieber Institute

April 3, 2014
Research and Development, Sales and Marketing Astellas, AstraZeneca, Lundbeck, Pfizer, Roche, ability, brain, lieber, lilly

Lundbeck has entered into a new partnership with the Lieber Institute for Brain Development in the hope of discovering new …

News

Aveo and Astellas part ways

February 17, 2014
Sales and Marketing Astellas, Aveo, Boehringer, EMA, tivozanib

Aveo Oncology and Astellas Pharma are to abandon their three-year old collaboration and licence agreement for investigational tyrosine kinase inhibitor …

News
sir michael parkinson image

Sir Michael Parkinson criticises NICE

February 4, 2014
Medical Communications, Sales and Marketing Astellas, NHS, NICE, Xtandi, parkinson, prostate

TV host Sir Michael Parkinson has told NICE that it must lift the restrictions imposed on Astellas’ new prostate cancer …

News

NICE looks at Xtandi again

January 28, 2014
Sales and Marketing Astellas, NHS, NICE, Xtandi

NICE has announced it is to consult again on its decision to recommend Astellas Pharma’s prostate cancer drug Xtandi after …

News

Astellas seeks Xtandi extension

December 5, 2013
Sales and Marketing Astellas, Cancer, EU, FDA, US, Xtandi

Astellas Pharma and development partner Medivation are seeking to extend the reach of oncology brand Xtandi by conducting a trial …

News
claire_thom_astellas

Astellas hires senior VP from rival Takeda

August 15, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Takeda, oncology

Astellas has appointed Claire Thom from fellow Japanese firm Takeda to be senior vice president of its global oncology development. …

Appointment
Cytokinetics image

Astellas in $500m deal with Cytokinetics

June 27, 2013
Sales and Marketing Astellas, cytokinetics

Astellas Pharma could pay out $40 million over the next two years to US firm Cytokinetics as part of a …

News

Xtandi gets EU approval

June 26, 2013
Sales and Marketing Astellas, FDA, Xtandi

Astellas Pharma’s Xtandi has been approved in the European Union for the treatment of adult men with advanced prostate cancer, …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025